TMEM86B: A Potential Drug Target for Neuroprotection and Disease Diagnosis

Target Name: TMEM86B

NCBI ID: G255043

TMEM86B

TMEM86B: A Potential Drug Target for Neuroprotection and Disease Diagnosis

TMEM86B (Lysoplasmalgenase (isoform 1)) is a protein that is expressed in a variety of tissues, including the brain, heart, and liver. It is a member of the superfamily of Mal peroxidase (SMAS-related), which includes proteins that play a role in cellular signaling and inflammation. TMEM86B is localized to the endoplasmic reticulum (ER) and has been shown to function as a negative regulator of the transcription factor Nrf2.

Nrf2 is a non-protein nuclear factor that plays a role in the detoxification of xenobiotics and other harmful substances. TMEM86B has been shown to physically interact with Nrf2 and to regulate its activity. This interaction between TMEM86B and Nrf2 suggests that TMEM86B may be a potential drug target or biomarker for the treatment of a variety of diseases.

One of the potential therapeutic applications of TMEM86B is its potential as a neuroprotectant. The brain is a particularly sensitive organ to xenobiotics and other harmful substances, and damage to the brain can have serious consequences. TMEM86B has been shown to protect against neurotoxicity in a variety of models, including the rat model of neurotoxicity.

In addition to its potential as a neuroprotectant, TMEM86B may also be a useful biomarker for the diagnosis of certain diseases. The levels of TMEM86B have been shown to be altered in a variety of diseases, including neurodegenerative disorders, cancer, and cardiovascular disease. This suggests that TMEM86B may be a potential indicator of disease status and may be used in the diagnosis of certain diseases.

TMEM86B is also of interest as a potential target for small molecules. The Nrf2 pathway is a well-established pathway for the detoxification of xenobiotics and other harmful substances, and TMEM86B may be a potential target for drugs that are able to modulate this pathway. The use of small molecules as therapeutic agents has become increasingly popular in recent years, and TMEM86B may be a valuable tool in this field.

TMEM86B is also of interest as a potential target for protein-protein interactions. The Nrf2 pathway is a complex process that involves the interaction of multiple proteins, including TMEM86B. The use of protein-protein interactions as therapeutic targets has become increasingly popular in recent years , and TMEM86B may be a valuable tool in this field.

In conclusion, TMEM86B is a protein that has been shown to function as a negative regulator of the Nrf2 pathway and to protect against neurotoxicity. Its potential as a neuroprotectant and biomarker makes it an attractive target for therapeutic intervention. The use of small molecules and protein -protein interactions as therapeutic targets also suggest that TMEM86B may be a valuable tool in the development of new drugs for a variety of diseases.

Protein Name: Transmembrane Protein 86B

Functions: Enzyme catalyzing the degradation of lysoplasmalogen. Lysoplasmalogens are formed by the hydrolysis of the abundant membrane glycerophospholipids plasmalogens. May control the respective levels of plasmalogens and lysoplasmalogens in cells and modulate cell membrane properties

The "TMEM86B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM86B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets